Weight Loss
Human studies found large average reductions in body weight. Most of the weight lost came from body fat, although results differed between people.
Metabolic Signaling Research
Reta + GHK-Cu Bundle
1 × Retatrutide 10 mg + 1 × GHK-Cu 50 mg
This bundle contains one Retatrutide 10 mg product and one GHK-Cu 50 mg product in separate packages. Their research topics and documents remain separate. The bundle does not prove a combined biological effect.
€110,00
1 × Retatrutide 10 mg
1 × GHK-Cu 50 mg
Each included product remains separately packaged and individually identified.
Research only
Secure checkout
For in-vitro laboratory research only. Not for human or veterinary use.This information is provided for scientific and educational product context only. It does not describe or recommend human use, veterinary use, diagnosis, treatment, prevention, dosage, administration, or clinical application.
At a glance
What It Does in the Body
Retatrutide
Less Hunger
It affects hunger and fullness signals. People may feel less hungry, become full sooner and find it easier to eat less.
Blood Sugar and Insulin
It helps the body release insulin when blood sugar rises. This can improve how the body handles sugar after eating.
GHK-Cu
Collagen
GHK-Cu is studied for how skin cells produce collagen. Collagen gives skin and other tissues strength and structure.
Skin Repair
Researchers study how GHK-Cu affects skin-cell movement and repair signals after tissue damage.
The two products were studied separately; no combined effect is claimed.
Bundle details
Two products with separate research information
This bundle contains Retatrutide 10 mg and GHK-Cu 50 mg in separate packages. Each product has its own research topics, evidence and documents. The bundle does not prove a combined biological or clinical effect.
Included products
Two separately packaged reference products
Each product keeps its own name, image, batch details and document status.
1 vial included
Retatrutide — 10 mg
Metabolic Signaling Research
Retatrutide is studied for hormone systems linked with hunger, blood sugar and energy use. Human trial results apply to the specific investigational drug, not this laboratory product.
- Included amount
- 10 mg / vial
- Packaging
- Separately packaged
Analytical documentation
Retatrutide — 10 mg
Applies only to the product and batch identified on the document.
1 vial included
GHK-Cu — 50 mg
Dermal and Matrix Research
GHK-Cu is a short peptide bound to copper. Researchers mainly study collagen signals, cell movement and the material that supports tissues.
- Included amount
- 50 mg / vial
- Packaging
- Separately packaged
Analytical documentation
GHK-Cu — 50 mg
Applies only to the product and batch identified on the document.
Bundle record
Bundle facts
- Included products
- 1 × Retatrutide — 10 mg
1 × GHK-Cu — 50 mg - Packaging
- Components are separately packaged and individually identified.
- Product identity
- Each component retains its own product and batch identity.
- Documentation
- Documents remain specific to the identified component and batch.
- Availability
- Bundle availability depends on both linked component inventories.
- Current price
- €110,00
Component documentation
Each product has its own documents
Use the document button in each product card. A record applies only to the product and batch it names. No combined analytical record is claimed.
Full research details
Full details for each product
What the two compounds are
Retatrutide and GHK-Cu are two separate research products. Retatrutide activates three hormone receptors. GHK-Cu is a short peptide bound to copper. They have different targets, evidence and unknowns. Evidence for one product cannot be applied to the other, and placing them in one bundle does not prove a combined or stronger effect.
- Material
- Two separately packaged peptide reference products
- Components
- Retatrutide — 10 mg and GHK-Cu — 50 mg
- Primary research areas
- Metabolic signaling and dermal/matrix research
- Evidence
- Component-specific and formulation-dependent
- Catalog
- Metabolic Signaling Research / Dermal and Matrix Research
What researchers think Retatrutide does in the body
- GLP-1 and GIP receptors normally coordinate food-related insulin, glucose, appetite and digestion signals.
- The glucagon receptor normally helps maintain glucose supply and mobilise stored energy.
- Retatrutide activates all three receptors, so researchers study the balance of their signals.
- Human trials measured body weight and HbA1c; frequent adverse effects included nausea, diarrhoea, vomiting and constipation.
What researchers think GHK-Cu does in the body
- GHK binds copper, which is normally used by enzymes involved in tissue structure and cell chemistry.
- Cell and animal work reports changes in collagen-related, cell-movement and wound-model markers.
- A tiny topical human study found no objective improvement on its main skin assessments.
- Raw-material human effects and a reliable adverse-effect profile are not established.
What laboratory and animal research can evaluate
- Identity of each included component
- Component-specific analytical documentation
- Stability under defined laboratory conditions
- Results for each separately handled material
- Responses in an assay, meaning a controlled laboratory test
- Comparison with a separate control for each component
- Documentation and batch traceability
Current evidence snapshot
| Evidence area | Context | Strength | Notes |
|---|---|---|---|
| Retatrutide laboratory research | Receptor and cell-signalling studies | Mechanistic | Researchers have examined GLP-1, GIP and glucagon receptor activation. |
| Retatrutide animal research | Metabolic models | Preclinical | Animal observations do not by themselves predict results in people. |
| Retatrutide human research | Phase 2 and phase 3 trials | Meaningful investigational evidence | Trials reported lower body-weight and blood-glucose measures. Results apply to the exact investigational product and study conditions, not this listing. |
| GHK-Cu laboratory research | Copper binding and cell models | Preclinical | Studies measure matrix, cell-movement and stress-related signals. |
| GHK-Cu animal research | Controlled wound models | Preclinical | Model-specific tissue markers do not establish a human outcome. |
| GHK-Cu human research | 13-person topical study | Very limited | No objective advantage was found on the main skin assessments; satisfaction was higher. This does not establish a result for raw GHK-Cu. |
| Combined bundle outcome | Retail bundle | Not established | No combined biological, cosmetic or clinical effect is claimed. |
Component references
Background records remain component-specific
These existing individual-product references provide component-level background. They are not evidence for a combined bundle outcome.
Retatrutide component references
Retatrutide phase 3 diabetes trial
View Retatrutide — 10 mg
PubMed / Lancet · 2026
HbA1c, body-weight and adverse-event results for an investigational product.
Triple-hormone-receptor agonist retatrutidePubMed / NEJM · 2023
Phase 2 body-weight and adverse-event context.
Structural basis of retatrutide triple agonismPubMed · 2024
Receptor-structure and signaling context.
Retatrutide study NCT04881760ClinicalTrials.gov · 2023
Official investigational study record.
GHK-Cu component references
Topical GHK-Cu after laser resurfacing
View GHK-Cu — 50 mg
PubMed · 2006
Small human study with no objective advantage on the main skin assessments.
GHK-Cu in a controlled scald-wound modelPubMed · 2017
Experimental vascular and repair-marker context.
GHK-Cu and LPS-induced signaling responsesPubMed · 2016
Cell and controlled-model signaling context.
Bundle FAQ
What is included in the bundle?
One Retatrutide — 10 mg vial and one GHK-Cu — 50 mg vial.
Are the products separately packaged?
Yes. Each product is separately packaged and individually identified.
Does one analytical document apply to both products?
No. Each document applies only to the component and batch identified on that record.
What determines bundle availability?
Availability follows the selected bundle variant and the inventory of both linked components.